Phase I, Double Blind, Randomized, Parallel-Arm, Single-Dose, Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator (Avastin®, Roche) in Healthy Male Volunteers

Trial Profile

Phase I, Double Blind, Randomized, Parallel-Arm, Single-Dose, Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator (Avastin®, Roche) in Healthy Male Volunteers

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Cancer; Colorectal cancer
  • Focus Pharmacokinetics
  • Sponsors TRPHARM
  • Most Recent Events

    • 10 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as per decision of the sponsor
    • 12 Sep 2017 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2017.
    • 02 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top